Franklin Parlapiano Turner & Welch LLC Has $5.39 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Franklin Parlapiano Turner & Welch LLC raised its holdings in Johnson & Johnson (NYSE:JNJ) by 3.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 41,632 shares of the company’s stock after buying an additional 1,334 shares during the quarter. Johnson & Johnson accounts for 2.1% of Franklin Parlapiano Turner & Welch LLC’s investment portfolio, making the stock its 21st largest holding. Franklin Parlapiano Turner & Welch LLC’s holdings in Johnson & Johnson were worth $5,386,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Synovus Financial Corp raised its position in shares of Johnson & Johnson by 1.1% during the third quarter. Synovus Financial Corp now owns 307,807 shares of the company’s stock worth $39,810,000 after purchasing an additional 3,356 shares during the period. Independence Advisors LLC raised its position in shares of Johnson & Johnson by 216.1% during the third quarter. Independence Advisors LLC now owns 19,785 shares of the company’s stock worth $2,560,000 after purchasing an additional 13,526 shares during the period. IFM Investors Pty Ltd raised its position in shares of Johnson & Johnson by 52.2% during the third quarter. IFM Investors Pty Ltd now owns 286,744 shares of the company’s stock worth $37,099,000 after purchasing an additional 98,316 shares during the period. Wedge Capital Management L L P NC raised its position in shares of Johnson & Johnson by 16.1% during the third quarter. Wedge Capital Management L L P NC now owns 285,497 shares of the company’s stock worth $36,938,000 after purchasing an additional 39,609 shares during the period. Finally, Sandy Spring Bank raised its position in shares of Johnson & Johnson by 4.1% during the third quarter. Sandy Spring Bank now owns 134,015 shares of the company’s stock worth $17,339,000 after purchasing an additional 5,318 shares during the period. 72.25% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have recently weighed in on the company. Morgan Stanley reaffirmed an “equal weight” rating and set a $145.00 target price on shares of Johnson & Johnson in a research report on Tuesday, August 27th. Bank of America reissued a “hold” rating and issued a $150.00 price target on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Sanford C. Bernstein raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target for the company in a research report on Friday, October 11th. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Finally, Goldman Sachs Group set a $169.00 price target on Johnson & Johnson and gave the company a “buy” rating in a research report on Tuesday, August 27th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Johnson & Johnson has a consensus rating of “Buy” and an average target price of $151.64.

NYSE JNJ traded up $1.57 on Friday, reaching $133.00. The company had a trading volume of 4,856,974 shares, compared to its average volume of 7,224,392. The stock has a market capitalization of $343.25 billion, a P/E ratio of 16.26, a P/E/G ratio of 2.20 and a beta of 0.69. The company’s fifty day moving average is $130.83 and its 200 day moving average is $134.05. Johnson & Johnson has a 52-week low of $121.00 and a 52-week high of $148.99. The company has a quick ratio of 1.00, a current ratio of 1.26 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 EPS for the quarter, beating analysts’ consensus estimates of $2.00 by $0.12. The business had revenue of $20.73 billion during the quarter, compared to analyst estimates of $20.14 billion. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. Johnson & Johnson’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.05 EPS. On average, research analysts expect that Johnson & Johnson will post 8.65 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 2.86%. The ex-dividend date of this dividend is Monday, November 25th. Johnson & Johnson’s payout ratio is currently 46.45%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: What is the Moving Average Convergence Divergence (MACD) oscillator?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply